Switch to
Predicate | Object |
---|---|
rdf:type | |
lifeskim:mentions | |
pubmed:issue |
10
|
pubmed:dateCreated |
1988-11-21
|
pubmed:abstractText |
Previous short-term studies have shown that the dopamine agonist pergolide improves control of Parkinson's disease when used in conjunction with carbidopa-levodopa (Sinemet). We assessed the long-term outcome (2 1/2- to 3-year follow-up) in patients with Parkinson's disease who participated in our previous pergolide double-blind trial and were subsequently switched to open-label pergolide therapy. Of 41 evaluable patients who began pergolide therapy, 10 (24%) experienced sustained substantial benefit that persisted to the end of this investigation. A total of 23 patients (56%) remained on pergolide therapy and, as a group, had considerable improvement over baseline at 2 1/2 to 3 years on the basis of several measurements of efficacy. A tendency toward deterioration could be reversed in many patients by larger or more frequent doses of carbidopa-levodopa; nevertheless, all but four patients were still taking the same dose or less of carbidopa-levodopa at the end of this study as at the onset. Patients with the best initial response to pergolide seemed most likely to experience long-term benefit. Confusion and hallucinations were the side effects most likely to necessitate discontinuation of pergolide. Symptoms suggestive of dose-related angina pectoris occurred in four patients in the open-label phase and two patients in the earlier double-blind phase (13% of patients who started pergolide therapy); these symptoms were easily controlled by dose reduction or discontinuation of pergolide, without sequelae. Dose-related leukopenia developed in one patient.
|
pubmed:language |
eng
|
pubmed:journal | |
pubmed:citationSubset |
AIM
|
pubmed:chemical | |
pubmed:status |
MEDLINE
|
pubmed:month |
Oct
|
pubmed:issn |
0025-6196
|
pubmed:author | |
pubmed:issnType |
Print
|
pubmed:volume |
63
|
pubmed:owner |
NLM
|
pubmed:authorsComplete |
Y
|
pubmed:pagination |
979-87
|
pubmed:dateRevised |
2007-11-15
|
pubmed:meshHeading |
pubmed-meshheading:3050301-Aged,
pubmed-meshheading:3050301-Carbidopa,
pubmed-meshheading:3050301-Clinical Trials as Topic,
pubmed-meshheading:3050301-Double-Blind Method,
pubmed-meshheading:3050301-Drug Therapy, Combination,
pubmed-meshheading:3050301-Follow-Up Studies,
pubmed-meshheading:3050301-Humans,
pubmed-meshheading:3050301-Levodopa,
pubmed-meshheading:3050301-Middle Aged,
pubmed-meshheading:3050301-Parkinson Disease,
pubmed-meshheading:3050301-Pergolide,
pubmed-meshheading:3050301-Placebos,
pubmed-meshheading:3050301-Retrospective Studies
|
pubmed:year |
1988
|
pubmed:articleTitle |
Pergolide: long-term use in Parkinson's disease.
|
pubmed:affiliation |
Department of Neurology, Mayo Clinic Scottsdale, Arizona.
|
pubmed:publicationType |
Journal Article,
Clinical Trial,
Research Support, Non-U.S. Gov't
|